| scholarly article | Q13442814 |
| P50 | author | Alan R. Zinsmeister | Q64368056 |
| Darren Burton | Q125486958 | ||
| P2093 | author name string | M Camilleri | |
| P Carlson | |||
| B S Wong | |||
| M I Vazquez-Roque | |||
| P2860 | cites work | Identification of membrane-type receptor for bile acids (M-BAR) | Q24316461 |
| A G protein-coupled receptor responsive to bile acids | Q24338558 | ||
| Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis | Q24635181 | ||
| Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function | Q24647522 | ||
| Endogenous bile acids are ligands for the nuclear receptor FXR/BAR | Q28198990 | ||
| Bile acids, farnesoid X receptor, atherosclerosis and metabolic control | Q28301806 | ||
| Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis | Q33682175 | ||
| Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions | Q33780740 | ||
| Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort | Q33780866 | ||
| Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence | Q33854022 | ||
| Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders | Q34603143 | ||
| Scintigraphic biomarkers for colonic dysmotility | Q35384517 | ||
| Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders | Q35596567 | ||
| Bile acid metabolism and the pathogenesis of type 2 diabetes | Q35917864 | ||
| The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism | Q36204119 | ||
| Bile acids: short and long term effects in the intestine. | Q37718243 | ||
| Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? | Q37737870 | ||
| Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. | Q39726655 | ||
| Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. | Q40456537 | ||
| The proximal colonic motor response to rectal mechanical and chemical stimulation | Q43884238 | ||
| A study of candidate genotypes associated with dyspepsia in a U.S. community | Q46932419 | ||
| Assessment of functional gastrointestinal disease: the bowel disease questionnaire | Q68591715 | ||
| Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets | Q73889603 | ||
| Performance characteristics of scintigraphic transit measurements for studies of experimental therapies | Q77067415 | ||
| Is there an association between GNbeta3-C825T genotype and lower functional gastrointestinal disorders? | Q83953267 | ||
| Missing link identified: GpBAR1 is a neuronal bile acid receptor | Q84420221 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 995-9, e458 | |
| P577 | publication date | 2011-08-24 | |
| P1433 | published in | Neurogastroenterology and Motility | Q15767493 |
| P1476 | title | Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders | |
| P478 | volume | 23 |
| Q34412381 | Advances in understanding of bile acid diarrhea |
| Q34724632 | Bacterial bile metabolising gene abundance in Crohn's, ulcerative colitis and type 2 diabetes metagenomes |
| Q94527115 | Bile Acid Receptors and Gastrointestinal Functions |
| Q38364542 | Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa |
| Q38198859 | Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy |
| Q28244875 | Bile acid signaling in metabolic disease and drug therapy |
| Q35817782 | Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion |
| Q38550878 | Drug discovery approaches to irritable bowel syndrome |
| Q51318198 | Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. |
| Q28244603 | Elobixibat and its potential role in chronic idiopathic constipation |
| Q37635259 | GPBA: a GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation |
| Q34131127 | Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion |
| Q92106425 | Intestinal Absorption of Bile Acids in Health and Disease |
| Q48389586 | Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches |
| Q37575689 | Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit |
| Q37629670 | Irritable bowel syndrome: emerging paradigm in pathophysiology |
| Q26860280 | Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome |
| Q26751193 | Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment |
| Q38194905 | Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract |
| Q28273649 | Review article: bile acid diarrhoea - pathogenesis, diagnosis and management |
| Q38241386 | TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis? |
| Q38177434 | The bile acid TGR5 membrane receptor: from basic research to clinical application |
| Q38183448 | The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention. |
| Q38217671 | The role of bile acids in functional GI disorders. |
| Q55555487 | What Has Bariatric Surgery Taught Us About the Role of the Upper Gastrointestinal Tract in the Regulation of Postprandial Glucose Metabolism? |
Search more.